UPDATED May 09, 2024
Companies with a Future performance score of at least 3, ordered by Future performance score.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
NEWBRY | kr3.06 | -5.6% | -43.3% | kr74.2m | kr8.00 | PS3.3x | E112.9% | n/a | Pharmaceuticals & Biotech | ||
KEBNI B | kr1.48 | -3.0% | 43.5% | kr402.4m | kr2.20 | PS4.4x | E90.4% | n/a | Tech | ||
CALTX | kr112.00 | 3.0% | -13.0% | kr6.0b | kr208.00 | PS5x | E49.9% | n/a | Pharmaceuticals & Biotech | ||
AESI | US$22.99 | 4.8% | 34.1% | US$2.5b | US$26.00 | PE20.4x | E49.3% | 3.7% | Energy | ||
AXSM | US$73.68 | -0.7% | -5.5% | US$3.6b | US$123.56 | PS13.9x | E65.1% | n/a | Pharmaceuticals & Biotech | ||
ADOC | €8.61 | 2.4% | 149.9% | €123.0m | €9.70 | PS20.3x | E104.5% | n/a | Pharmaceuticals & Biotech | ||
ELF | US$170.43 | 6.2% | 90.3% | US$9.0b | US$205.92 | PE73.1x | E26.4% | n/a | Household | ||
TGTX | US$16.92 | 3.0% | -49.8% | US$2.5b | US$31.50 | PE58.8x | E48.0% | n/a | Pharmaceuticals & Biotech | ||
AGP | €8.32 | 0% | 155.2% | €144.0m | €12.75 | PE29.3x | E22.8% | n/a | Capital Goods | ||
ARES | US$142.44 | 5.8% | 74.8% | US$43.0b | US$147.64 | PE64.2x | E41.9% | 2.6% | Diversified Financials | ||
APLT | US$4.62 | 2.0% | 180.0% | US$538.1m | US$11.60 | PS52.8x | E81.9% | n/a | Pharmaceuticals & Biotech | ||
AVLL3 | R$3.78 | 1.1% | 26.4% | R$738.3m | R$9.90 | PS1.6x | E101.9% | n/a | Consumer Durables | ||
ATAKP | ₺44.30 | -5.7% | n/a | ₺6.1b | ₺67.66 | PE20.8x | E72.8% | n/a | Food, Beverage & Tobacco | ||
FDE | €35.30 | 0.4% | 0.9% | €184.6m | €64.07 | PE23.5x | E37.6% | n/a | Energy | ||
ASND | US$133.13 | -5.6% | 38.8% | US$7.7b | US$180.08 | PS26.4x | E65.0% | n/a | Pharmaceuticals & Biotech | ||
RDUE | €9.65 | 1.0% | 2.2% | €60.3m | €10.50 | PE17.8x | E37.7% | n/a | Capital Goods | ||
FWRY | ج.م6.07 | 2.4% | 5.4% | ج.م20.7b | ج.م7.20 | PE33.5x | E34.8% | n/a | Diversified Financials | ||
OSE | €7.00 | 12.2% | 81.8% | €151.0m | €7.15 | PS67.8x | E92.9% | n/a | Pharmaceuticals & Biotech | ||
ZVRA | US$5.03 | 5.9% | 18.1% | US$215.9m | US$19.00 | PS7.6x | E65.7% | n/a | Pharmaceuticals & Biotech | ||
NVG | zł2.18 | 9.0% | 34.6% | zł76.3m | zł3.71 | PE15.1x | E29.0% | n/a | Diversified Financials | ||
RCEL | US$8.71 | -0.1% | -44.6% | US$231.2m | US$25.90 | PS4.5x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
NVDA | US$887.47 | 3.4% | 210.5% | US$2.2t | US$1,004.20 | PE73.4x | E23.4% | 0.02% | Semiconductors | ||
ERO | CA$29.84 | 4.7% | 25.6% | CA$3.0b | CA$31.13 | PE36.5x | E31.5% | n/a | Materials | ||
A179900 | ₩33,900.00 | -3.1% | 56.9% | ₩536.4b | ₩60,000.00 | PS27.7x | E111.6% | 0% | Tech |